Karthick Vishwanathan

3.1k total citations · 1 hit paper
64 papers, 2.2k citations indexed

About

Karthick Vishwanathan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Karthick Vishwanathan has authored 64 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 30 papers in Molecular Biology and 30 papers in Oncology. Recurrent topics in Karthick Vishwanathan's work include Lung Cancer Treatments and Mutations (29 papers), PI3K/AKT/mTOR signaling in cancer (16 papers) and Colorectal Cancer Treatments and Studies (9 papers). Karthick Vishwanathan is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), PI3K/AKT/mTOR signaling in cancer (16 papers) and Colorectal Cancer Treatments and Studies (9 papers). Karthick Vishwanathan collaborates with scholars based in United States, United Kingdom and South Korea. Karthick Vishwanathan's co-authors include James T. Stewart, Michael G. Bartlett, Myung‐Ju Ahn, Yuichiro Ohe, Randall L. Tackett, Andy Brown, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn H. Brown and Helen Mann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Karthick Vishwanathan

63 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Geoffrey R. Oxnard, J.C.-H. Yang et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Karthick Vishwanathan

Since Specialization

Citations

This map shows the geographic impact of Karthick Vishwanathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karthick Vishwanathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karthick Vishwanathan more than expected).

Fields of papers citing papers by Karthick Vishwanathan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karthick Vishwanathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karthick Vishwanathan. The network helps show where Karthick Vishwanathan may publish in the future.

Co-authorship network of co-authors of Karthick Vishwanathan

This figure shows the co-authorship network connecting the top 25 collaborators of Karthick Vishwanathan. A scholar is included among the top collaborators of Karthick Vishwanathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karthick Vishwanathan. Karthick Vishwanathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessing Trends in Cytokine–CYP Drug Interactions and Relevance to Drug Dosing 2024 ·Drug Metabolism and Disposition ·Aarti Sawant‐Basak, (unknown), David L. Dai, Karthick Vishwanathan, Alex Phipps	1
2	Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study 2023 ·Clinical and Translational Science ·Simon Ekman, Zsolt Cselényi, Andrea Varrone, Aurelija Jučaitė, (unknown), Magnus Schou, Peter Johnström, Gianluca Laus, Rolf Lewensohn, Andy Brown, Jasper van der Aart, Karthick Vishwanathan, Lars Farde	7
3	A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers 2023 ·Clinical Pharmacology in Drug Development ·(unknown), Karthick Vishwanathan, Graeme Scarfe, Yan Li, (unknown), Mireille Cantarini, John R. Argue, (unknown)	3
4	Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy 2022 ·British Journal of Clinical Pharmacology ·(unknown), Diansong Zhou, Hua Wei, (unknown), (unknown), Jean Cheung, (unknown), R. Lai, Shringi Sharma, Karthick Vishwanathan, Joseph A. Ware	8
5	Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies 2021 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), Karthick Vishwanathan, Helen Wei, (unknown), (unknown), (unknown), Huan Liu, Marshall Baek, Joseph A. Ware, Priti Patel, Helen Tomkinson, Shringi Sharma	14
6	Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach 2021 ·British Journal of Clinical Pharmacology ·(unknown), Francesco Bellanti, Huan Liu, Karthick Vishwanathan, Helen Tomkinson, Joseph A. Ware, Shringi Sharma, (unknown)	9
7	Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors 2021 ·Cancer Chemotherapy and Pharmacology ·Venkatesh Pilla Reddy, Adrian J. Fretland, Diansong Zhou, Shringi Sharma, Buyun Chen, Karthick Vishwanathan, Dermot F. McGinnity, Yan Xu, Joseph A. Ware	8
8	Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas 2021 ·Cancer Chemotherapy and Pharmacology ·Stein Schalkwijk, Li Zhou, (unknown), Lokesh Jain, Tomoko Freshwater, Karen So, (unknown), (unknown), Helen Tomkinson, Karthick Vishwanathan, Diansong Zhou	10
9	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment 2020 ·Pharmacology Research & Perspectives ·Karthick Vishwanathan, (unknown), Bhumsuk Keam, Nicolas Penel, Maria J. de Miguel, (unknown), Andrew C. Mills, Marcelo Marotti, Martin Johnson, Alain Ravaud	9
10	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer breakdown → 2020 ·Annals of Oncology ·Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu, Seung‐Whan Kim, Hideo Saka, Leora Horn, Kōichi Goto, Yuichiro Ohe, Helen Mann, Kenneth S. Thress, Melanie M. Frigault, Karthick Vishwanathan, Dana Ghiorghiu, Suresh S. Ramalingam, Myung‐Ju Ahn	303
11	P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases 2019 ·Journal of Thoracic Oncology ·Simon Ekman, Andrea Varrone, Aurelija Jučaitė, Karthick Vishwanathan, Alan S. Brown, Zsolt Cselényi, (unknown), Rolf Lewensohn, Magnus Schou, Gianluca Laus, (unknown), Peter Johnström, Neha Singh, Lars Farde	1
12	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis 2019 ·Journal of Thoracic Oncology ·Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng, Ji‐Youn Han, Sarah B. Goldberg, Alastair Greystoke, Jeffrey Crawford, Yanqiu Zhao, Xiangning Huang, Martin Johnson, Karthick Vishwanathan, James Yates, Andy Brown, Ariadna Mendoza‐Naranjo, Tony Mok	100
13	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers 2018 ·British Journal of Cancer ·Jörge E. Cortes, Kenji Tamura, Daniel J. DeAngelo, Johann S. de Bono, David Lorente, Mark D. Minden, Geoffrey L. Uy, Hagop M. Kantarjian, Lisa S. Chen, Varsha Gandhi, Robert Godin, Karen Keating, Kristen McEachern, Karthick Vishwanathan, J. Elizabeth Pease, Emma Dean	83
14	Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents 2016 ·Xenobiotica ·Jian Guo, Camil Joubran, (unknown), Gregory S. Basarab, Scott Grimm, Karthick Vishwanathan	7
15	Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen 2016 ·Antiviral Research ·Jeremy R. Duvall, Lynn VerPlank, Barbara Ludeke, Sarah M. McLeod, Maurice D. Lee, Karthick Vishwanathan, Carol A. Mulrooney, (unknown), Qin Yu, Michelle Palmer, Paul Fleming, Rachel Fearns, Michael A. Foley, Christina Scherer	11
16	Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach 2016 ·Drug Metabolism and Disposition ·Barry Jones, (unknown), Susanne Johansson, Kajsa P. Kanebratt, Craig Lambert, Karthick Vishwanathan, Tommy B. Andersson	32
17	Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential 2014 ·Drug Metabolism and Disposition ·Karthick Vishwanathan, Stuart Mair, Anshul Gupta, James Atherton, (unknown), Timi Edeki, Shampa Das	42
18	In vitroandin vivometabolism of¹⁴C-AZ11, a novel inhibitor of bacterial DNA gyrase/type II topoisomerase 2014 ·Xenobiotica ·Jian Guo, Camil Joubran, (unknown), Fei Zhou, Gregory S. Basarab, Karthick Vishwanathan	3
19	Contribution of Artifacts to N-Methylated Piperazine Cyanide Adduct Formation In Vitro from N-Alkyl Piperazine Analogs 2013 ·Drug Metabolism and Disposition ·Minli Zhang, (unknown), Jian Guo, Mark Powell, Charles S. Elmore, Jun Hu, Karthick Vishwanathan	3
20	Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry 2000 ·Rapid Communications in Mass Spectrometry ·Karthick Vishwanathan, Michael G. Bartlett, James T. Stewart	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact